Abstract
Over the past few decades, treatment advances have made significant progress toward improving and extending the lives of patients with cancer. But what is the cost of extended survival? Is there a point at which our health-care system has to say “no” to costly new agents? Editor-in-Chief Pamela Hallquist Viale weighs in regarding the economic burden of cancer care.
